Para Advisors’s Pfizer PFE Stock Holding History

Para Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-105,400	Closed	-$3.14M	–	24
2015 Q3	$3.14M	Sell	105,400 -52,700	-33%	-$1.69M	8.43%	3
2015 Q2	$5.03M	Buy	158,100 +52,700	+50%	+$1.72M	7.18%	3
2015 Q1	$3.48M	Hold	105,400	–	–	3.19%	9
2014 Q4	$3.12M	Hold	105,400	–	–	6.03%	5
2014 Q3	$2.96M	Buy	+105,400	New	+$2.96M	1.82%	20

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Para Advisors's PFE Position: Q4 2015 in Review

Para Advisors sold out of Pfizer (PFE) in Q4 2015, closing a stake of 105,400 shares — an estimated $3.14M sold.

Para Advisors first reported a position in PFE in Q3 2014 and held it in 5 quarters. The position peaked at $5.03M in Q2 2015. 1,969 funds tracked by Wall St. Rank hold PFE as of Q4 2015.

Para Advisors reported no remaining Pfizer position as of Q4 2015 after selling out during the quarter.
Para Advisors sold 105,400 Pfizer shares in Q4 2015, an estimated $3.14M.
Para Advisors first reported a position in Pfizer in Q3 2014 and held it in 5 quarters.
Para Advisors's Pfizer position peaked at $5.03M in Q2 2015.
1,969 funds tracked by Wall St. Rank held Pfizer as of Q4 2015.

Based on Para Advisors's 13F filing for Q4 2015, filed 16 Feb 2016.